Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

The Aphria-Tilray Merger Shows Just How Overpriced Canopy Growth Is

By David Jagielski - Jan 7, 2021 at 6:50AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Its $10 billion valuation is more than triple the market cap of both merging companies -- combined.

Cannabis producers Aphria ( APHA ) and Tilray ( TLRY ) rocked the industry when they announced last month that they were merging to create the largest cannabis company in the world (based on pro forma revenue). The move instantly creates a new leading cannabis company in Canada, and one that could become a big competitor in the U.S. market once pot is legal at the federal level.

For a long time, many cannabis investors saw Canopy Growth ( CGC -3.57% ) as the industry leader. But with the company struggling to generate sales growth, there are much better pot stocks to buy. And the deal with Aphria and Tilray only makes matters worse, as it creates a powerhouse that's a much better bargain than Canopy Growth.

A marijuana leaf on a dollar bill.

Image source: Getty Images. 

Aphria was already ahead of Canopy Growth in terms of revenue

Even before the companies announced this deal, Aphria was arguably already a better buy than Canopy Growth. Over the trailing 12 months, Aphria has reported revenue of 561 million Canadian dollars ($443 million). And although it doesn't cover the exact same period, Canopy Growth's sales during its last four quarters totaled just CA$477 million ($377 million) -- 15% less revenue than Aphria. Yet investors are paying considerably more for Canopy Growth, with a market cap of $10 billion, than they are for Aphria and its $2.2 billion valuation. 

Once you add Tilray into the mix, the discrepancy becomes even more lopsided. The British Columbia-based company's top line has been fairly consistent, typically hovering around the $50 million mark every quarter. Over the trailing 12 months, its sales have totaled $201 million. Add that to Aphria's sales and you're looking at combined revenue of about $644 million. In their merger announcement, however, the companies estimated their pro forma revenue to be $685 million, which could be due to the slightly different quarterly schedules that they're on. Tilray's current valuation of $1.5 billion is even lower than Aphria's and would put the two companies at a combined value of around $3.5 billion -- still nowhere near Canopy Growth's astronomical price despite significantly higher top lines.

That means investors would be paying a little over 5 times revenue for the combined company. Canopy Growth, meanwhile, trades at a price-to-sales ratio of more than 27. Here's a look at the stocks individually:

TLRY PS Ratio Chart

TLRY PS Ratio data by YCharts

There's no denying the huge disparity between the companies and their respective valuations, which leads to the inevitable question of ...

Why are investors paying such a premium for Canopy Growth?

Often, investors are willing to pay more for a company if they expect its future growth numbers to be very strong. A big advantage Canopy Growth enjoys over its peers today is a partnership with beer maker Constellation Brands that gives it financial stability. The two have also been working on cannabis-infused beverages for the Canadian pot market. In addition, investors are likely bullish about the prospect of Canopy Growth entering the U.S. market, as it has a tentative deal in place to acquire Acreage Holdings once it's legal to do so.

While those are advantages, they're not likely to make Canopy Growth's stock five times more valuable. Tilray has its own beverage partnership with Anheuser-Busch. And while the Budweiser-maker didn't directly invest in Tilray the way Constellation did in Canopy Growth, the two did enter into a joint venture that could be beneficial for both companies. 

Aphria and Tilray also don't have an agreement in place with a multistate operator, but Canopy Growth's deal is still technically not complete. And Aphria may be taking a more conservative approach to investing in the U.S. pot market after receiving a warning from the Toronto Stock Exchange in 2018 that its shares could be delisted for its ownership of cannabis assets in the U.S. under Liberty Health Sciences. Aphria eventually divested itself of those investments, so it may not be all that surprising that it hasn't been as aggressive as Canopy Growth when it comes to U.S. expansion. But once legalization takes place, the combined company could still broker a deal of its own (and it could also work on one in the interim, given that it could still be years before the U.S. fully legalizes marijuana).

The advantages that Canopy Growth has right now just aren't enough to make it worth significantly more than Aphria, Tilray, or the combined entity once the merger completes -- which the companies expect will happen in the second quarter of this year.

Should you buy shares of Aphria and Tilray instead of Canopy Growth?

If you're looking to invest in a pot stock today, Aphria and Tilray are certainly much better buys than Canopy Growth, particularly because they're joining forces. However, because I expect the combined entity to struggle out of the gate (given that acquisition-related expenses and inefficiencies may negatively impact its first few quarters), it may be wise to wait a little bit before investing. The valuation of Tilray (which is the name that will be used post-merger) may fall after the transaction is complete, at least in the early stages. But over the long term, it looks to be a promising buy, and Tilray could become a major player in the North American cannabis industry.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Canopy Growth Stock Quote
Canopy Growth
CGC
$9.99 (-3.57%) $0.37
Constellation Brands, Inc. Stock Quote
Constellation Brands, Inc.
STZ
$226.19 (0.41%) $0.93
Anheuser-Busch InBev SA/NV Stock Quote
Anheuser-Busch InBev SA/NV
BUD
$56.46 (0.11%) $0.06
Tilray Stock Quote
Tilray
TLRY
Liberty Health Sciences Inc. Stock Quote
Liberty Health Sciences Inc.
LHSIF
Aphria Stock Quote
Aphria
APHA
Acreage Holdings, Inc. Stock Quote
Acreage Holdings, Inc.
ACRGF

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
624%
 
S&P 500 Returns
141%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/04/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.